Income Statement Voyageur Pharmaceuticals Ltd. OTC Markets
Stocks
VYYRF
CA92918C1014
Pharmaceuticals
|
Market Closed -
OTC Markets
12:31:15 2026-03-24 EDT
|
5-day change | 1st Jan Change | ||
| 0.1080 USD | +2.86% |
|
-4.00% | -16.99% |
| Fiscal Period: November | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | - | - | - | - | 11.68K | |||||
Total Revenues | - | - | - | - | 11.68K | |||||
Cost of Goods Sold, Total | - | - | - | - | 11.68K | |||||
Gross Profit | - | - | - | - | 0 | |||||
Selling General & Admin Expenses, Total | 1.23M | 1.45M | 987K | 1.1M | 2.08M | |||||
Exploration / Drilling Costs, Total | - | - | - | - | - | |||||
Stock-Based Compensation (IS) | 738K | 152K | 234K | 417K | 810K | |||||
Depreciation & Amortization - (IS) | 2.25K | 2.91K | 2.18K | 1.57K | 1.13K | |||||
Impairment of Oil, Gas & Mineral Properties - (IS) | - | - | - | - | - | |||||
Other Operating Expenses, Total | 1.97M | 1.61M | 1.22M | 1.51M | 2.89M | |||||
Operating Income | -1.97M | -1.61M | -1.22M | -1.51M | -2.89M | |||||
Interest Expense, Total | - | - | - | - | - | |||||
Net Interest Expenses | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | -77.21K | -147K | -123K | -184K | -639K | |||||
EBT, Excl. Unusual Items | -2.05M | -1.75M | -1.35M | -1.7M | -3.53M | |||||
Merger & Related Restructuring Charges | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | - | -6.21K | - | - | - | |||||
Asset Writedown | - | - | -48.61K | -7.94K | - | |||||
Other Unusual Items | - | 4.24K | -4.48K | - | - | |||||
EBT, Incl. Unusual Items | -2.05M | -1.75M | -1.4M | -1.71M | -3.53M | |||||
Earnings From Continuing Operations | -2.05M | -1.75M | -1.4M | -1.71M | -3.53M | |||||
Net Income to Company | -2.05M | -1.75M | -1.4M | -1.71M | -3.53M | |||||
Net Income - (IS) | -2.05M | -1.75M | -1.4M | -1.71M | -3.53M | |||||
Net Income to Common Incl Extra Items | -2.05M | -1.75M | -1.4M | -1.71M | -3.53M | |||||
Net Income to Common Excl. Extra Items | -2.05M | -1.75M | -1.4M | -1.71M | -3.53M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | |||||
Basic EPS - Continuing Operations | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | |||||
Basic Weighted Average Shares Outstanding | 94.68M | 108M | 131M | 138M | 166M | |||||
Net EPS - Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | |||||
Diluted EPS - Continuing Operations | -0.02 | -0.02 | -0.01 | -0.01 | -0.02 | |||||
Diluted Weighted Average Shares Outstanding | 94.68M | 108M | 131M | 138M | 166M | |||||
Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |||||
Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | |||||
Supplemental Items | ||||||||||
EBITDA | -1.97M | -1.6M | -1.22M | -1.51M | -2.89M | |||||
EBITA | -1.97M | -1.61M | -1.22M | -1.51M | -2.89M | |||||
EBIT | -1.97M | -1.61M | -1.22M | -1.51M | -2.89M | |||||
EBITDAR | - | - | - | - | - | |||||
Normalized Net Income | -1.28M | -1.09M | -841K | -1.06M | -2.21M | |||||
Supplemental Operating Expense Items | ||||||||||
Marketing Expenses | 497K | 528K | 281K | 287K | 908K | |||||
Selling and Marketing Expenses | 497K | 528K | 281K | 287K | 908K | |||||
General and Administrative Expenses | 418K | 511K | 376K | 466K | 762K | |||||
Research And Development Expense From Footnotes | - | - | - | - | 0 | |||||
Exploration/Drilling Costs | - | - | - | - | - | |||||
Net Rental Expense, Total | - | - | - | - | - | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | - | - | |||||
Stock-Based Comp., Other (Total) | 738K | 152K | 234K | 417K | 810K | |||||
Total Stock-Based Compensation | 738K | 152K | 234K | 417K | 810K |
Select your edition
All financial news and data tailored to specific country editions
